A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer

References

• BubendorfLSchopferAWagnerUMetastatic patterns of prostate cancer: an autopsy study of 1,589 patientsHum Pathol200031557858310836297
   PubMed Web of Science ®Google Scholar
• ColemanREMetastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treat Rev200127316517611417967
   PubMed Web of Science ®Google Scholar
• ColemanRERisks and benefits of bisphosphonatesBr J Cancer200898111736174018506174
   PubMed Web of Science ®Google Scholar
• BerensonJRRosenLSHowellAZoledronic acid reduces skeletal-related events in patients with osteolytic metastasesCancer20019171191120011283917
   PubMed Web of Science ®Google Scholar
• SaadFClinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancerClin Prostate Cancer200541313715992459
   PubMedGoogle Scholar
• SaadFChenYMGleasonDMChinJContinuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastasesClin Genitourin Cancer20075639039617956712
   PubMed Web of Science ®Google Scholar
• SmithMRZoledronic acid to prevent skeletal complications in cancer: corroborating the evidenceCancer Treat Rev200531Suppl 3192516229955
   PubMedGoogle Scholar
• MarxRESawatariYFortinMBroumandVBisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatmentJ Oral Maxillofac Surg200563111567157516243172
   PubMed Web of Science ®Google Scholar
• ReidIROsteonecrosis of the jaw: who gets it, and why?Bone200944141018948230
   PubMed Web of Science ®Google Scholar
• MarxREPamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJ Oral Maxillofac Surg20036191115111712966493
   PubMed Web of Science ®Google Scholar
• BamiasAKastritisEBamiaCOsteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factorsJ Clin Oncol200523348580858716314620
   PubMed Web of Science ®Google Scholar
• BonomiMNortilliRMolinoARenal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysisMed Oncol27222422919330470
   PubMed Web of Science ®Google Scholar
• CetinerSSucakGTKahramanSAOsteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acidJ Bone Miner Metab200927443544319240969
   PubMed Web of Science ®Google Scholar
• JaduFLeeLPharoahMReeceDWangLA retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patientsAnn Oncol200718122015201917804475
   PubMed Web of Science ®Google Scholar
• LehrerSMontazemARamanathanLBisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate geneJ Oral Maxillofac Surg200967115916119070762
   PubMed Web of Science ®Google Scholar
• OrtegaCMontemurroFFaggiuoloROsteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysisActa Oncol200746566466817562443
   PubMed Web of Science ®Google Scholar
• KhoslaSBurrDCauleyJBisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res200722101479149117663640
   PubMed Web of Science ®Google Scholar
• Aragon-ChingJBNingYMChenCCHigher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agentsCancer Invest200927222122619235596
   PubMed Web of Science ®Google Scholar
• WalterCAl-NawasBGrotzKAPrevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronateEur Urol20085451066107218602738
   PubMed Web of Science ®Google Scholar
• BadrosAWeikelDSalamaAOsteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factorsJ Clin Oncol200624694595216484704
   PubMed Web of Science ®Google Scholar
• RuggieroSLDodsonTBAssaelLALandesbergRMarxREMehrotraBAmerican Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw – 2009 updateAust Endod J200935311913019961450
   PubMed Web of Science ®Google Scholar
• ChristodoulouCPervenaAKlouvasGCombination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates aloneOncology200976320921119212145
   PubMed Web of Science ®Google Scholar
• ZervasKVerrouETeleioudisZIncidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patientsBr J Haematol2006134662062316889620
   PubMed Web of Science ®Google Scholar
• LazaroviciTSYahalomRTaicherSEladSHardanIYaromNBisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patientsJ Oral Maxillofac Surg200967485085519304045
   PubMed Web of Science ®Google Scholar
• SarasqueteMEGarcia-SanzRMarinLBisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysisBlood200811272709271218594024
   PubMed Web of Science ®Google Scholar
• RoelofsAJThompsonKGordonSRogersMJMolecular mechanisms of action of bisphosphonates: current statusClin Cancer Res20061220 Pt 26222s6230s17062705
   PubMed Web of Science ®Google Scholar
• DaikhBELaskerJMRaucyJLKoopDRRegio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9J Pharmacol Exp Ther19942713142714337996455
   PubMed Web of Science ®Google Scholar
• WeblerACMichaelisURPoppREpoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesisAm J Physiol Cell Physiol20082955C1292C130118787075
   PubMed Web of Science ®Google Scholar
• BackmanUSvenssonAChristoffersonRHAzarbayjaniFThe bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesisAnticancer Res.2008283A1551155718630510
   PubMed Web of Science ®Google Scholar
• SoltauJZirrgiebelUEsserNAntitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA modelAnticancer Res2008282A93394118507039
   PubMed Web of Science ®Google Scholar
• TangXZhangQShiSBisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cellsInt J Cancer201012619010319569175
   PubMed Web of Science ®Google Scholar
• JungTIHoffmannFGlaeskeGFelsenbergDDisease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapyJ Cancer Res Clin Oncol2010136336337019701651
   PubMed Web of Science ®Google Scholar